Examkin

Question

Difficulty: Very hardChildhood and Neurodevelopmental Disorders

A 9-year-old boy is brought to the clinic by his parents due to academic difficulties and new behavioral habits. Over the past 14 months, his parents have noticed him frequently and forcefully blinking his eyes, shrugging his shoulders, and clearing his throat. The parents initially attributed the throat clearing to seasonal allergies, but a two-month trial of daily cetirizine provided no relief. His teacher reports that he frequently leaves his seat during class, interrupts others, and struggles to sustain focus on assignments, which is severely impacting his grades. He has no history of sudden behavioral changes following infections. The physician diagnoses a neurodevelopmental disorder and recommends starting a medication that can simultaneously address both his movement symptoms and his behavioral difficulties. Which of the following describes the mechanism of action of the most appropriate initial pharmacotherapy for this patient?

  1. Agonism at central alpha-2 adrenergic receptorsAnswer
  2. B
    Inhibition of presynaptic dopamine and norepinephrine reuptake
  3. C
    Selective inhibition of presynaptic norepinephrine reuptake
  4. D
    Antagonism at postsynaptic dopamine D2 and serotonin 5-HT2A receptors
  5. E
    Selective inhibition of presynaptic serotonin reuptake

Answer

Agonism at central alpha-2 adrenergic receptors
The patient's clinical presentation of multiple motor tics (eye blinking, shoulder shrugging) and at least one vocal tic (throat clearing) persisting for over a year is diagnostic of Tourette syndrome. Concurrently, his inattention, hyperactivity, and impulsivity causing academic impairment are diagnostic of comorbid Attention-Deficit/Hyperactivity Disorder (ADHD). When Tourette syndrome and ADHD co-occur, central alpha-2 adrenergic agonists (such as guanfacine and clonidine) are the most appropriate initial pharmacological choice because they demonstrate efficacy in simultaneously reducing the severity of tics and improving ADHD symptoms. Their mechanism of action is agonism at central alpha-2 adrenergic receptors, which enhances prefrontal cortical regulation of attention and impulse control.

Step-by-Step Solution

1
Analyze the patient's movement and vocal symptoms.
The patient has multiple motor tics (eye blinking, shoulder shrugging) and a vocal tic (throat clearing) lasting more than 1 year (14 months).
To establish the diagnosis of Tourette syndrome and rule out transient tic disorder or allergies.
2
Analyze the patient's behavioral and academic symptoms.
The patient exhibits hyperactivity (leaving seat), impulsivity (interrupting), and inattention (struggles to sustain focus) causing severe academic impairment.
To establish the comorbid diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD).
3
Determine the optimal pharmacological management for the combined diagnoses.
Alpha-2 adrenergic agonists (guanfacine or clonidine) are indicated.
They uniquely provide dual efficacy, reducing both tic severity and ADHD symptoms, making them the preferred initial monotherapy for this specific comorbidity.
4
Identify the mechanism of action of the chosen medication.
Guanfacine and clonidine act via agonism at central alpha-2 adrenergic receptors.
To answer the specific question asked in the stem regarding the neuropharmacology of the optimal drug.

Key Concept

Patients with comorbid Tourette syndrome and Attention-Deficit/Hyperactivity Disorder (ADHD) are typically best managed initially with central alpha-2 adrenergic agonists (e.g., guanfacine, clonidine), which effectively target both symptom clusters.
Rate this question

Topics

Childhood and Neurodevelopmental Disorders

More questions from this topic